Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 71335-1646

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 71335-1646). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Clopidogrel Fig)

A chart depicting the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite exposure of Clopidogrel 75 mg following multiple doses. The graph shows mean values with 90% confidence intervals comparing exposure with Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg relative to Clopidogrel administered alone.*

FDA Label Image

Figure3 (Clopidogrel Fig2)

A line graph showing cumulative event rates (%) for cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two groups are compared: placebo plus aspirin and clopidogrel plus aspirin, with the clopidogrel group showing a lower event rate. The graph notes use of other standard therapies as appropriate and includes a statistical significance value (P=0.00009).*

FDA Label Image

Figure3 (Clopidogrel Fig3)

A forest plot displaying hazard ratios with 95% confidence intervals for various subgroups comparing Clopidogrel bisulfate to placebo. Subgroups include age, gender, race, presence of elevated cardiac enzymes, diabetes, previous myocardial infarction, previous stroke, use of Heparin/LMWH, aspirin dosage, GP IIb/IIIa antagonist use, beta-blocker use, and ACE inhibitor use. The plot visually indicates which subgroups favor Clopidogrel or placebo based on hazard ratios.*

FDA Label Image

Figure4 (Clopidogrel Fig4)

A line graph showing cumulative event rates for death in the COMMIT study over 28 days since randomization. The y-axis measures the percentage dead before first discharge, ranging from 0 to 9%. Two lines compare Placebo and Clopidogrel groups, indicating 8.1% deaths for Placebo and 7.5% for Clopidogrel, with a noted 7% proportional risk reduction (p=0.03). A footnote states all treated patients received aspirin.*

FDA Label Image

Figure5 (Clopidogrel Fig5)

A line chart showing percentage of patients with death, re-infarction, or stroke before first discharge over 28 days since randomization. Two curves compare placebo (10.1% event rate) and Clopidogrel (9.2% event rate) groups, noting a 9% proportional risk reduction (p=0.002) for Clopidogrel.*

FDA Label Image

Figure6 (Clopidogrel Fig6)

A forest plot showing effects of adding Clopidogrel to Aspirin on combined primary endpoints across various medication subgroups in the COMMIT study. Subgroup categories include gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent status, with odds ratios and confidence intervals indicating favorability toward Clopidogrel or placebo.*

FDA Label Image

Figure7 (Clopidogrel Fig7)

A line graph showing the cumulative event rate (%) of fatal or non-fatal vascular events over months of follow-up. The chart compares two groups labeled ASPIRIN and CLOPIDOGREL, depicting cumulative event rates rising from 0 to around 14-16% over 36 months. A p-value of 0.045 is noted indicating statistical comparison between the groups.*

FDA Label Image

Figure8 (Clopidogrel Fig8)

A forest plot graph titled 'Hazard Ratio and 95% CI by Baseline Subgroups in the CAPRIE Study.' It displays hazard ratios with 95% confidence intervals for subgroups Stroke, MI, PAD, and Overall, comparing Clopidogrel versus Aspirin. The x-axis ranges from 0.6 to 1.3 indicating hazard ratio values, with markers showing the point estimates and confidence intervals for each subgroup.*

FDA Label Image

Structure (Clopidogrel Str)

Chemical structure of clopidogrel bisulfate showing the molecular framework with rings and functional groups including chlorine, sulfur, oxygen, and nitrogen atoms, along with H2SO4 indicating the bisulfate salt form.*

FDA Label Image

Label Image (Lbl713351646)

Label for Clopidogrel 75 mg tablet, film coated, packaged by Bryant Ranch Prepack. The label indicates the product is a prescription drug with NDC 71335-1646-1 and compares it to Plavix 75 mg tablet by ScieGen Pharmaceuticals, Inc. The package contains 90 tablets, and storage instructions advise keeping the container tightly closed at 20°-25°C (68°-77°F).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.